相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus
Pierre-Louis Herve et al.
VACCINE (2021)
De novo protein design enables the precise induction of RSV-neutralizing antibodies
Fabian Sesterhenn et al.
SCIENCE (2020)
A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain
Kurt A. Swanson et al.
SCIENCE IMMUNOLOGY (2020)
IGF1R is an entry receptor for respiratory syncytial virus
Cameron D. Griffiths et al.
NATURE (2020)
Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
Jessica Marcandalli et al.
CELL (2019)
Respiratory syncytial virus entry and how to block it
Michael B. Battles et al.
NATURE REVIEWS MICROBIOLOGY (2019)
A proof of concept for structure-based vaccine design targeting RSV in humans
Michelle C. Crank et al.
SCIENCE (2019)
Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients
Xunyan Ye et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Natalie I. Mazur et al.
LANCET INFECTIOUS DISEASES (2018)
Dendritic Cell Sensing of Hydrophobic Di-and Triacylated Lipopeptides Self-Assembled within Synthetic Virus-like Particles
Rajni Sharma et al.
JOURNAL OF IMMUNOLOGY (2017)
Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant
Kirsten Schneider-Ohrum et al.
JOURNAL OF VIROLOGY (2017)
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
Patricio L. Acosta et al.
CLINICAL AND VACCINE IMMUNOLOGY (2016)
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats
Christina A. Rostad et al.
JOURNAL OF VIROLOGY (2016)
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
Jarrod J. Mousa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation
Christopher C. Stobart et al.
NATURE COMMUNICATIONS (2016)
Novel antigens for RSV vaccines
Barney S. Graham et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets
Cory J. Knudson et al.
PLOS PATHOGENS (2015)
Proof of principle for epitope-focused vaccine design
Bruno E. Correia et al.
NATURE (2014)
Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein
John T. Bates et al.
VIROLOGY (2014)
Refining the Balance of Attenuation and Immunogenicity of Respiratory Syncytial Virus by Targeted Codon Deoptimization of Virulence Genes
Jia Meng et al.
MBIO (2014)
Group- and Genotype-Specific Neutralizing Antibody Responses Against Respiratory Syncytial Virus in Infants and Young Children With Severe Pneumonia
Charles J. Sande et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus
Vivian Luchsinger et al.
CLINICAL INFECTIOUS DISEASES (2012)
Engineered Synthetic Virus-Like Particles and Their Use in Vaccine Delivery
Arin Ghasparian et al.
CHEMBIOCHEM (2011)
Synthetic Virus-Like Particles and Conformationally Constrained Peptidomimetics in Vaccine Design
Tina Riedel et al.
CHEMBIOCHEM (2011)
Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab
Qing Zhu et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus
Jason S. McLellan et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Structural basis of respiratory syncytial virus neutralization by motavizumab
Jason S. McLellan et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Synthetic Viruslike Particles and Hybrid Constructs Based on Lipopeptide Self-Assembly
Adam W. Perriman et al.
SMALL (2010)
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract
Herren Wu et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system
Francesca Boato et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2007)
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine
GA Prince et al.
JOURNAL OF GENERAL VIROLOGY (2001)
Influence of maternal antibodies on neonatal immunization against respiratory viruses
JE Crowe
CLINICAL INFECTIOUS DISEASES (2001)
分享论文
